Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Nephros (NEPH) Enterprise Value (2016 - 2025)

Nephros has reported Enterprise Value over the past 16 years, most recently at -$5.4 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$5.4 million for Q4 2025, down 43.62% from a year ago — trailing twelve months through Dec 2025 was -$5.4 million (down 43.62% YoY), and the annual figure for FY2025 was -$5.4 million, down 43.62%.
  • Enterprise Value for Q4 2025 was -$5.4 million at Nephros, down from -$5.2 million in the prior quarter.
  • Over the last five years, Enterprise Value for NEPH hit a ceiling of -$345000.0 in Q4 2022 and a floor of -$5.4 million in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$4.0 million (2021), compared with a mean of -$3.6 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 91.2% in 2022 and later tumbled 1148.41% in 2023.
  • Nephros' Enterprise Value stood at -$3.9 million in 2021, then skyrocketed by 91.2% to -$345000.0 in 2022, then tumbled by 1148.41% to -$4.3 million in 2023, then rose by 12.7% to -$3.8 million in 2024, then tumbled by 43.62% to -$5.4 million in 2025.
  • The last three reported values for Enterprise Value were -$5.4 million (Q4 2025), -$5.2 million (Q3 2025), and -$5.1 million (Q2 2025) per Business Quant data.